Given the elevated expression of Bcl-xL in HCC cells, we evaluated the therapeutic effects of ABT-263, a potent Bcl-2 family inhibitor that has been used for treatment of other cancers such as small-cell lung cancer and lymphoid malignancies clinically. Here, BCL2 is linked to small cell lung carcinoma.